ROCKWELL MEDICAL INC (RMTI)
US7743743004 - Common Stock
Overall RMTI gets a fundamental rating of 2 out of 10. We evaluated RMTI against 188 industry peers in the Health Care Equipment & Supplies industry. RMTI has a bad profitability rating. Also its financial health evaluation is rather negative. RMTI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RMTI has reported negative net income.
RMTI had a negative operating cash flow in the past year.
In the past 5 years RMTI always reported negative net income.
In the past 5 years RMTI always reported negative operating cash flow.
1.2 Ratios
RMTI has a Return On Assets (-9.00%) which is in line with its industry peers.
RMTI has a better Return On Equity (-20.31%) than 60.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | -20.31% | ||
| ROIC | N/A |
ROA(3y)-41.16%
ROA(5y)-48.05%
ROE(3y)-486.08%
ROE(5y)-343.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 13.44%, RMTI is not doing good in the industry: 81.28% of the companies in the same industry are doing better.
RMTI's Gross Margin has improved in the last couple of years.
RMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y33.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
RMTI has more shares outstanding than it did 1 year ago.
RMTI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RMTI has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.16, we must say that RMTI is in the distress zone and has some risk of bankruptcy.
RMTI has a Altman-Z score of -7.16. This is in the lower half of the industry: RMTI underperforms 73.26% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that RMTI is not too dependend on debt financing.
RMTI has a Debt to Equity ratio (0.43) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.16 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
A Current Ratio of 2.00 indicates that RMTI should not have too much problems paying its short term obligations.
RMTI has a worse Current ratio (2.00) than 68.45% of its industry peers.
RMTI has a Quick Ratio of 1.60. This is a normal value and indicates that RMTI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of RMTI (1.60) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 80.00% over the past year.
RMTI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.38%.
The Revenue has been growing slightly by 5.69% on average over the past years.
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%177.54%
Revenue 1Y (TTM)22.38%
Revenue growth 3Y10.36%
Revenue growth 5Y5.69%
Sales Q2Q%19.12%
3.2 Future
Based on estimates for the next years, RMTI will show a very strong growth in Earnings Per Share. The EPS will grow by 47.60% on average per year.
The Revenue is expected to grow by 15.20% on average over the next years. This is quite good.
EPS Next Y92.35%
EPS Next 2Y47.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.03%
Revenue Next 2Y13.78%
Revenue Next 3Y14.67%
Revenue Next 5Y15.2%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RMTI. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 31.51, which means the current valuation is very expensive for RMTI.
Based on the Price/Forward Earnings ratio, RMTI is valued a bit cheaper than 73.80% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.56. RMTI is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.51 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RMTI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RMTI's earnings are expected to grow with 47.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.6%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for RMTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ROCKWELL MEDICAL INC
NASDAQ:RMTI (11/21/2024, 9:38:03 AM)
2.25
-0.08 (-3.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap68.22M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.51 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | -20.31% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y92.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.38%
Revenue growth 3Y10.36%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y